NCT00508001View on ClinicalTrials.gov

Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC)

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

June 30, 2009

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Vandetanib

ZD6474 300mg

DRUG

Vandetanib

ZD6474 100 mg

DRUG

Best Supportive Care

Placebo + Best Supportive Care

Trial Locations (3)

Unknown

Research Site, Tainan City

Research Site, Taipei

Research Site, Taoyuan District

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00508001 - Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) | Biotech Hunter | Biotech Hunter